Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

Lecouvet, Frédéric E and Oprea-Lager, Daniela E and Liu, Yan and Ost, Piet and Bidaut, Luc and Collette, Laurence and Deroose, Christophe M and Goffin, Karolien and Herrmann, Ken and Hoekstra, Otto S and Kramer, Gem and Lievens, Yolande and Lopci, Egesta and Pasquier, David and Petersen, Lars J and Talbot, Jean-Noël and Zacho, Helle and Tombal, Bertrand and deSouza, Nandita M (2018) Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, 19 . e534-e545. ISSN 1470-2045

Full content URL: https://www.sciencedirect.com/science/article/pii/...

Documents
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group
[img]
[Download]
[img] PDF
L Bidaut - Use of modern imaging....pdf - Whole Document
Available under License Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.

1MB
Item Type:Article
Item Status:Live Archive

Abstract

Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasisdirected therapies. These therapies potentially shorten or postpone the use of systemic treatment and can delay further metastatic progression, thus increasing overall survival. Metastasis-directed therapies require imaging methods that definitively recognise oligometastatic disease to validate their efficacy and reliably monitor response, particularly so that morbidity associated with inappropriately treating disease subsequently recognised as polymetastatic can be avoided. In this Review, we assess imaging methods used to identify metastatic prostate cancer at first diagnosis, at biochemical recurrence, or at the castration-resistant stage. Standard imaging methods recommended by guidelines have insufficient diagnostic accuracy for reliably diagnosing oligometastatic disease. Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases. The European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group suggests clinical algorithms to integrate modern imaging methods into the care pathway at the various stages of prostate cancer to identify oligometastatic disease. The EORTC proposes clinical trials that use modern imaging methods to evaluate the benefits of metastasis-directed therapies.

Additional Information:The final published version of this article can be accessed online at https://www.sciencedirect.com/science/article/pii/S1470204518305710
Keywords:Medical Imaging, Oligometastatic disease, EORTC
Subjects:A Medicine and Dentistry > A300 Clinical Medicine
B Subjects allied to Medicine > B100 Anatomy, Physiology and Pathology
B Subjects allied to Medicine > B820 Radiology
B Subjects allied to Medicine > B900 Others in Subjects allied to Medicine
Divisions:College of Science > School of Computer Science
ID Code:33696
Deposited On:29 Oct 2018 08:45

Repository Staff Only: item control page